Identification and saturable nature of signaling pathways induced by metreleptin in humans: Comparative evaluation of in vivo, ex vivo, and in vitro administration

Diabetes

Volumn 64, Issue 3, 2015, Pages 828-839

  Moon, Hyun Seuk ^a,c   Huh, Joo Young ^a,d   Dincer, Fadime ^a   Schneider, Benjamin E ^b   Hasselgren, Per Olof ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Korea University   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METRELEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN KINASE B; STAT3 PROTEIN; LEPTIN;

ADIPOSE TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; LEAN BODY WEIGHT; LIPOLYSIS; MALE; MUSCLE; MUSCLE CELL; MYOMETRIUM; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ADULT; ANALOGS AND DERIVATIVES; CELL CULTURE; CLINICAL TRIAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; SKELETAL MUSCLE; WESTERN BLOTTING;

ADIPOSE TISSUE; ADULT; BLOTTING, WESTERN; CELLS, CULTURED; FEMALE; HUMANS; IN VITRO TECHNIQUES; LEPTIN; LEUKOCYTES, MONONUCLEAR; LIPOLYSIS; MIDDLE AGED; MUSCLE, SKELETAL; SIGNAL TRANSDUCTION;

EID: 84962110354     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0625     Document Type: Article

References (45)

1. Moon HS, Dalamaga M, Kim SY, et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 2013;34: 377-412
2. Carlton ED, Demas GE, French SS. Leptin, a neuroendocrine mediator of immune responses, inflammation, and sickness behaviors. Horm Behav 2012;62: 272-279
3. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2010; 31:377-393
4. Lee Y, Yu X, Gonzales F, et al. PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A 2002;99:11848-11853
5. Papathanassoglou E, El-Haschimi K, Li XC, Matarese G, Strom T, Mantzoros C. Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice. J Immunol 2006;176:7745-7752
6. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004;53(Suppl. 1):S152-S158
7. Schwartz MW, Baskin DG, Bukowski TR, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996;45:531-535
8. Ebihara K, Ogawa Y, Masuzaki H, et al. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 2001;50:1440-1448
9. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 2011;7:137-150
10. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002; 87:2395
11. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-578
12. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109: 1345-1350
13. Ebihara K, Masuzaki H, Nakao K. Long-term leptin-replacement therapy for lipoatrophic diabetes. N Engl J Med 2004;351:615-616
14. Moon HS, Chamberland JP, Mantzoros CS. Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C2C12 muscle and AML12 liver cell lines. Diabetologia 2012;55:215-225
15. Guo K, McMinn JE, Ludwig T, et al. Disruption of peripheral leptin signaling in mice results in hyperleptinemia without associated metabolic abnormalities. Endocrinology 2007;148:3987-3997
16. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002;26:1407-1433
17. Moon HS, Matarese G, Brennan AM, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 2011;60:1647-1656
18. Wolf G. Insulin resistance associated with leptin deficiency in mice: a possible model for noninsulin-dependent diabetes mellitus. Nutr Rev 2001;59:177-179
19. German JP, Wisse BE, Thaler JP, et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes 2010;59:1626-1634
20. Moon HS, Chamberland JP, Diakopoulos KN, et al. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diabetes Care 2011;34:132-138
21. Gouni-Berthold I, Berthold HK, Huh JY, et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS ONE 2013;8:e72858
22. Moon HS, Lee HG, Seo JH, et al. Lipolysis is stimulated by PEGylated conjugated linoleic acid through the cyclic adenosine monophosphateindependent signaling pathway in 3T3-L1 cells: activation of MEK/ERK MAPK signaling pathway and hyper-secretion of adipo-cytokines. J Cell Physiol 2008; 214:283-294
23. Chang L, Yang R, Wang M, et al. Angiotensin II type-1 receptor-JAK/STAT pathway mediates the induction of visfatin in angiotensin II-induced cardiomyocyte hypertrophy. Am J Med Sci 2012;343:220-226
24. Buettner C, Pocai A, Muse ED, Etgen AM, Myers MG Jr, Rossetti L. Critical role of STAT3 in leptin's metabolic actions. Cell Metab 2006;4:49-60
25. Sanchez-Margalet V, Martin-Romero C. Human leptin signaling in human peripheral blood mononuclear cells: activation of the JAK-STAT pathway. Cell Immunol 2001;211:30-36
26. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 2005;4:1131-1133
27. Wolsk E, Mygind H, Grøndahl TS, Pedersen BK, van Hall G. The role of leptin in human lipid and glucose metabolism: the effects of acute recombinant human leptin infusion in young healthy males. Am J Clin Nutr 2011;94:1533-1544
28. Berti L, Gammeltoft S. Leptin stimulates glucose uptake in C2C12 muscle cells by activation of ERK2. Mol Cell Endocrinol 1999;157:121-130
29. Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Mol Cell Biol 2007;27:4317-4327
30. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343
31. Steinberg GR, McAinch AJ, Chen MB, et al. The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. J Clin Endocrinol Metab 2006;91:3592-3597
32. Steinberg GR, Parolin ML, Heigenhauser GJ, Dyck DJ. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002;283:E187-E192
33. Carver KC, Piazza TM, Schuler LA. Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells. J Biol Chem 2010;285:8003-8012
34. Kolli S, Zito CI, Mossink MH, Wiemer EA, Bennett AM. The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. J Biol Chem 2004;279:29374-29385
35. Bjørbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001;276:4747-4755
36. Feng GS. Shp2 as a therapeutic target for leptin resistance and obesity. Expert Opin Ther Targets 2006;10:135-142
37. Goldberg AC, Eliaschewitz FG, Montor WR, et al. Exogenous leptin restores in vitro T cell proliferation and cytokine synthesis in patients with common variable immunodeficiency syndrome. Clin Immunol 2005;114:147-153
38. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001;15:2565-2571
39. Matarese G, La Rocca C, Moon HS, et al. Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia. Proc Natl Acad Sci U S A 2013;110:E818-E827
40. Yekollu SK, Thomas R, O'Sullivan B. Targeting curcusomes to inflammatory dendritic cells inhibits NF-kB and improves insulin resistance in obese mice. Diabetes 2011;60:2928-2938
41. Famulla S, Horrighs A, Cramer A, Sell H, Eckel J. Hypoxia reduces the response of human adipocytes towards TNFa resulting in reduced NF-kB signaling and MCP-1 secretion. Int J Obes (Lond) 2012;36:986-992
42. Wong SL, DePaoli AM, Lee JH, Mantzoros CS. Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. J Clin Endocrinol Metab 2004;89:2672-2677
43. Chan JL, Wong SL, Mantzoros CS. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin Pharmacokinet 2008; 47:753-764
44. Chan JL, Wong SL, Orlova C, Raciti P, Mantzoros CS. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay. J Clin Endocrinol Metab 2007;92:2307-2311
45. Pocai A, Morgan K, Buettner C, Gutierrez-Juarez R, Obici S, Rossetti L. Central leptin acutely reverses diet-induced hepatic insulin resistance. Diabetes 2005;54:3182-3189